SCHEMBL1703583

SCHEMBL1703583

Cn1nc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)cncc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 13/20 1.00
FLT1 P17948 10/20 1.00
CSF1R P07333 10/20 1.00
FLT4 P35916 9/20 1.00
LYN P07948 7/20 1.00
BLK P51451 7/20 1.00
LCK P06239 7/20 1.00
EPHA2 P29317 6/20 1.00
AURKB Q96GD4 6/20 1.00
MAP4K2 Q12851 5/20 1.00
TAOK1 Q7L7X3 5/20 1.00
MKNK2 Q9HBH9 5/20 1.00
MAP3K20 Q9NYL2 5/20 1.00
RPS6KB1 P23443 5/20 1.00
NTRK2 Q16620 5/20 1.00
MAP4K4 O95819 4/20 1.00
MET P08581 4/20 1.00
FGFR1 P11362 4/20 1.00
FRK P42685 4/20 1.00
ROCK2 O75116 4/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL424307 0.90 KIT (0.81) KITFLT1CSF1RFLT4LYN
SCHEMBL1702951 0.88 KDR (0.80) KITFLT1CSF1RFLT4LYN
SCHEMBL1702898 0.87 KDR (1.00) KITFLT1CSF1RFLT4LYN
SCHEMBL1702965 0.86 KDR (0.79) KITFLT1CSF1RFLT4LYN
SCHEMBL1702879 0.86 KDR (1.00) KITFLT1CSF1RFLT4LYN
SCHEMBL3842232 0.83 KIT (0.70) KITFLT1CSF1RFLT4LYN
SCHEMBL1703074 0.82 KDR (0.78) KITFLT1CSF1RFLT4LYN
SCHEMBL1703605 0.81 KDR (1.00) KITFLT1CSF1RFLT4LYN
SCHEMBL1384538 0.81 KDR (0.71) KITFLT1CSF1RFLT4LYN
SCHEMBL1702841 0.81 KDR (0.78) KITFLT1CSF1RFLT4LYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP claimed
EP-1807424-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-18 EP claimed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US claimed
WO-2006050109-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-05-11 WO claimed
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP disclosed
US-7812166-B2 Kinase inhibitors ABBOTT LABORATORIES (US) 2010-10-12 US disclosed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178378-A1 Novel kinase inhibitors ABL1, MAP3K19, MAP3K20 KIT 426/4885FLT1 529/4885CSF1R 1265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.